3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
8
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
6
Colorectal Neoplasms
6
Stomach Neoplasms
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Rectal Neoplasms
4
Neoplasms
4
Nasopharyngeal Carcinoma
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Skin Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Glioblastoma
2
Advanced Solid Tumors
2
von Hippel-Lindau Disease
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Adenocarcinoma
1
Solid Tumors
1
Solid Tumor, Adult
1
Solid Tumor
1
Interventions
tremelimumab
4
Ipilimumab
4
lenvatinib
3
durvalumab
3
Nivolumab
3
pembrolizumab
2
balstilimab
2
Pemetrexed
2
Carboplatin
2
Bevacizumab
2
spartalizumab
1
relatlimab
1
poly ICLC
1
osimertinib
1
cemiplimab
1
Vemurafenib
1
Vascular Endothelial Growth Factor A
1
Standard of Care
1
Platinum
1
Peptides
1
Paclitaxel
1
Opdualag
1
Docetaxel
1
Capecitabine
1
Blood Specimen Collection
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
spartalizumab
×
1 year
×
Clear all
NCT05751928
2025-07-08
NEO-MIMAJOR
Biocad
Phase 3
Active not recruiting
411 enrolled